Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    klh | First posted from 06/01/2012 to 08/16/2012
Previous Study | Return to List | Next Study

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01644968
Recruitment Status : Completed
First Posted : July 19, 2012
Last Update Posted : May 17, 2022
Sponsor:
Information provided by (Responsible Party):
Providence Health & Services

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.

Condition or disease Intervention/treatment Phase
Advanced Cancer Drug: Cohort 1 anti-OX40 Drug: Cohort 2 anti-OX40 Drug: Cohort 3 anti-OX40 Biological: Tetanus Day 29 Biological: Tetanus Day 1 Biological: KLH Day 1 Biological: KLH Day 29 Phase 1

Detailed Description:
This study will evaluate the safety and determine the maximal tolerated dose of anti-OX40; evaluated the immune response to the study treatment; measure the pharmacokinetics of anti-OX40; monitor tumor regression, and identify the most biologically active dose of anti-OX40 to induce antigen-specific responses to a variety of immunogens.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Trial of a Monoclonal Antibody to OX40 in Patients With Advanced Cancer.
Actual Study Start Date : November 2003
Actual Primary Completion Date : May 2009
Actual Study Completion Date : April 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tetanus

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: KLH + anti-OX40
Day 1: KLH + anti-OX40; Day 3: anti-OX40; Day 4: anti-OX40; Day 29: Tetanus vaccine
 Drug: Cohort 1 anti-OX40
0.1 mg/kg anti-OX40 on days 1, 3, and 5

Drug: Cohort 2 anti-OX40
.4 mg/kg anti-OX40 on days 1, 3, and 5

Drug: Cohort 3 anti-OX40
2.0 mg/kg anti-OX40 on days 1, 3, and 5

Biological: Tetanus Day 29
Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
Other Name: Tetanus Toxoid, Tetanus Toxoid Adsorbed

Biological: KLH Day 1
1 mg KLH in 1 cc diluent subcutaneously on Day 1.
Other Name: Immucothel.
Experimental: Tetanus vaccine + anti-OX40
Day 1: Tetanus vaccine + anti-OX40; Day 3: anti-OX40; Day 5: anti-OX40; Day 29: KLH
 Drug: Cohort 1 anti-OX40
0.1 mg/kg anti-OX40 on days 1, 3, and 5

Drug: Cohort 2 anti-OX40
.4 mg/kg anti-OX40 on days 1, 3, and 5

Drug: Cohort 3 anti-OX40
2.0 mg/kg anti-OX40 on days 1, 3, and 5

Biological: Tetanus Day 1
Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
Other Name: Tetansu Toxoid, Tetanus Toxoid Adsorbed.

Biological: KLH Day 29
1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
Other Name: Immucothel.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Dose limiting toxicity [ Time Frame: 28 Days ]
    A dose limiting toxicity is defined as any grade >=3 hematologic (except lymphopenia) or non-hematologic toxicity (except hypothyroidism or vitiligo) that, in the opinion of the investigator is considered at lease possibly related to the study treatment. If DLT is observed in greater than two patient in any cohort, then the previous cohort will be the maximal tolerated dose.


Secondary Outcome Measures :
  1. Immune Response [ Time Frame: Pre-study, Days 5, 8, 15, 29, 36, 43, and 57. ]
    Blood tests and leukapheresis product will be collected to determine the response to three types of reporter antigens: (1) new antigen (keyhole limpet hemocyanin (KLH)), (2) recall protein antigen (tetanus), and (3) viral antigen (cytomegalovirus (CMV)). Changes in the number of antigens will be used to determine immune response.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with uncurable metastatic carcinoma, lymphoma, or sarcoma.
  • ECOG performance status 0, 1, 2
  • No active bleeding
  • No clinical coagulopathy
  • Anticipated lifespan greater than 12 weeks

Exclusion Criteria:

  • Active residual toxicity from prior therapies
  • Active Infection
  • HIV positive
  • Hepatitis B or C positive
  • Pregnant or nursing women
  • Requirement for oral steroids
  • Brain metastases
  • Presence or history of autoimmune disease
  • Shellfish or tetanus allergy
  • Splenomegaly
  • Lymph nodes greater than 10 cm in maximal diameter
  • Uncontrolled angina or class II or IV heart failure
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01644968


Locations
Layout table for location information
United States, Oregon
Providence Cancer Center
Portland, Oregon, United States, 97213
Sponsors and Collaborators
Providence Health & Services
Investigators
Layout table for investigator information
Principal Investigator: Brendan Curti, MD Providence Health & Services
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Providence Health & Services
ClinicalTrials.gov Identifier: NCT01644968    
Other Study ID Numbers: 03-066A
First Posted: July 19, 2012    Key Record Dates
Last Update Posted: May 17, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Providence Health & Services:
metastatic carcinoma
lymphoma
sarcoma
anti-OX40
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms